Literature DB >> 16283215

In vitro activity of quinupristin and dalfopristin in combination and alone against coryneform bacteria.

G Funke1, R Troxler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16283215     DOI： 10.1007/s10096-005-0036-4

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  11 in total

1.  Natural antibiotic susceptibility of recently established coryneform bacteria.

Authors:  R Troxler; G Funke; A Von Graevenitz; I Stock
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-05       Impact factor: 3.267

2.  In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual gram-positive species.

Authors:  Ronald N Jones; Douglas J Biedenbach; Tamara R Anderegg
Journal:  Diagn Microbiol Infect Dis       Date:  2002-02       Impact factor: 2.803

3.  Actinomyces europaeus sp. nov., isolated from human clinical specimens.

Authors:  G Funke; N Alvarez; C Pascual; E Falsen; E Akervall; L Sabbe; L Schouls; N Weiss; M D Collins
Journal:  Int J Syst Bacteriol       Date:  1997-07

4.  AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro.

Authors:  A Wookey; P J Turner; J M Greenhalgh; M Eastwood; J Clarke; C Sefton
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

5.  In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria.

Authors:  T Schülin; C B Wennersten; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  Minimal inhibitory concentrations and minimal bactericidal concentrations of quinupristin/dalfopristin against clinical isolates of Corynebacterium jeikeium and Listeria monocytogenes.

Authors:  L S Moore; B Schneider; W J Holloway
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

Review 7.  Clinical microbiology of coryneform bacteria.

Authors:  G Funke; A von Graevenitz; J E Clarridge; K A Bernard
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

8.  In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerrin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi Warren; Kerin Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

10.  In vitro activity of newer antibiotics against Corynebacterium jeikeium, Corynebacterium amycolatum and Corynebacterium urealyticum.

Authors:  J Sánchez Hernández; B Mora Peris; G Yagüe Guirao; N Gutiérrez Zufiaurre; J L Muñoz Bellido; M Segovia Hernández; J A García Rodríguez
Journal:  Int J Antimicrob Agents       Date:  2003-11       Impact factor: 5.283
View more
  2 in total

1.  The isolation of Corynebacterium coyleae from clinical samples: clinical and microbiological data.

Authors:  M I Fernández-Natal; J A Sáez-Nieto; R Fernández-Roblas; M Asencio; S Valdezate; S Lapeña; R H Rodríguez-Pollán; J M Guerra; J Blanco; F Cachón; F Soriano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11-09       Impact factor: 3.267

2.  Isolation of Corynebacterium ureicelerivorans from normally sterile sites in humans.

Authors:  M I Fernández-Natal; J A Sáez-Nieto; S Valdezate; R H Rodríguez-Pollán; S Lapeña; F Cachón; F Soriano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-12-17       Impact factor: 3.267
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.